UB562
TargetsDPP-1/CTSK
IndicationsBronchiectasis
ClinicalCN - Pre-PCC
TherapeuticsImmunology & Inflammation
ModalitiesSmall Molecule
Exclusive Summary
- • Dual DPP1/CTSK inhibition that concurrently ameliorates inflammation and airway remodeling.
- • Significantly superior in vivo efficacy over brensocatib in mice models.
- • Favorable safety and pharmacokinetic profile.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →